ClinicalTrials.gg
RecruitingNCT07775183Updated Aug 31, 2026

The Effects of Light-Targeted Balance Training on Balance, Functional Performance, and Fear of Falling in Individuals With a History of Falls

An interventional study of Light- Targeted Balance Training and Standard Balance Training in Accidental Falls, Balance Impairment and Fear of Falling, sponsored by Uskudar University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Uskudar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

In recent years, exercise programs based on visual stimuli have been reported to improve balance and motor control . However, studies investigating the effects of light-targeted balance training on balance, functional performance, and fear of falling in individuals with a history of falls are limited.

The aim of this study is to determine the effects of light-targeted balance training on balance, functional performance, and fear of falling in individuals with a history of falls. In addition, the study aims to investigate whether this training method provides additional benefits compared with traditional balance training. The findings of this study are expected to contribute to the development of rehabilitation programs aimed at preventing falls.

Read the detailed description

Inclusion Criteria

  1. Having experienced at least one fall within the previous 12 months.
  2. Being 18 years of age or older.
  3. Being able to walk independently or with the assistance of a walking aid.
  4. Being able to understand and follow verbal and visual instructions.
  5. Providing voluntary consent to participate in the study and signing the informed consent form.

Exclusion Criteria

  1. Presence of an acute orthopedic injury or an active musculoskeletal condition causing pain.
  2. Having undergone lower extremity surgery within the previous 6 months.
  3. Having advanced neurological disorders (e.g., advanced Parkinson's disease, advanced dementia).
  4. Having severe vestibular dysfunction or significant visual impairment.
  5. Having a cardiovascular condition that contraindicates exercise.
  6. Having advanced systemic diseases that significantly impair balance.
02

Conditions studied

  • Accidental Falls
  • Balance Impairment
  • Fear of Falling

Keywords

  • balance training
  • rehabilitation
  • functional performance
03

In context

Lead sponsor

Uskudar University is the lead sponsor of 170 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of at least one fall within the past 12 months
  • Age 18 years or older
  • Ability to walk independently or with an assistive device
  • Ability to understand and follow verbal and visual instructions
  • Voluntary participation in the study and provision of written by signing the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Acute orthopedic injury or an active musculoskeletal condition causing pain
  • History of lower extremity surgery within the past 6 months
  • Advanced neurological disorders (e.g., advanced Parkinson's disease, advanced dementia)
  • Severe vestibular dysfunction or significant visual impairment
  • Medical conditions that contraindicate exercise due to severe cardiovascular disease
  • Advanced systemic diseases that severely affect balance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants in this group will receive light-targeted balance training in addition to the standard program.

    Behavioral: Light- Targeted Balance Training

  • Active comparator
    Control Group

    Participants in this group will receive standard balance exercises.

    Behavioral: Standard Balance Training

Interventions

  • BehavioralLight- Targeted Balance Training

    Exercises aimed at improving coordination, balance, and functional performance using visual and auditory cues.

  • BehavioralStandard Balance Training

    Conventional balance training exercises.

06

What researchers measure

Primary outcomes

  1. Change in Balance Performance (Berg Balance Scale)

    Balance performance is assessed using the Berg Balance Scale (BBS). The scale consists of 14 functional tasks scored from 0 to 4. The total score ranges from 0 to 56, where higher scores indicate better balance and lower fall risk.

    Time frame: Baseline and after 8 weeks of intervention

Secondary outcomes

  1. Change in Functional Mobility (Timed Up and Go Test - TUG)

    Dynamic balance and mobility are assessed using the Timed Up and Go (TUG) test. The time (in seconds) taken to stand up from a chair, walk 3 meters, turn around, walk back, and sit down is recorded. Shorter completion times indicate better mobility.

    Time frame: Baseline and after 8 weeks of intervention

  2. Change in Dynamic Balance (Y-Balance Test)

    Dynamic postural control is evaluated using the Y-Balance Test (YBT) in anterior, posteromedial, and posterolateral reach directions for both lower extremities. Reach distance is normalized to limb length ((reach distance / limb length) x 100) and composite scores are calculated.

    Time frame: Baseline and after 8 weeks of intervention

  3. Change in Lower Body Strength (30-Second Chair Stand Test)

    Lower extremity functional muscle strength is measured using the 30-Second Chair Stand Test. The total number of full stands completed from a seated position in 30 seconds is recorded. A higher number of repetitions indicates greater lower body strength.

    Time frame: Baseline and after 8 weeks of intervention

  4. Change in Gait Speed (10-Meter Walk Test - 10MWT)

    Walking speed is assessed using the 10-Meter Walk Test (10MWT). Participants walk a 10-meter course at their comfortable and/or fast walking pace, and the time taken (in seconds) to traverse the intermediate 6 meters is recorded to calculate gait speed (m/s).

    Time frame: Baseline and after 8 weeks of intervention

  5. Change in Fear of Falling (Falls Efficacy Scale-International - FES-I)

    Fear of falling is evaluated using the 16-item Falls Efficacy Scale-International (FES-I). Each item is scored on a 4-point Likert scale from 1 (not at all concerned) to 4 (very concerned). Total score ranges from 16 to 64, with higher scores reflecting greater fear of falling.

    Time frame: Baseline and after 8 weeks of intervention

  6. Change in Balance Confidence (Activities-specific Balance Confidence Scale - ABC)

    Balance confidence is measured using the 16-item Activities-specific Balance Confidence (ABC) Scale. Participants rate their confidence in performing specific activities without losing balance on a scale from 0% to 100%. The overall score is the mean percentage across all items.

    Time frame: Baseline and after 8 weeks of intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Sep 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2026
First posted
Aug 20, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07775183
Lead sponsor
Uskudar University
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Jul 31, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Aug 31, 2026

Study contacts

Shirin Khezritomatari
Contact
shirin.khezry8401@gmail.com
+905342494709

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion